{{Drugbox
| verifiedrevid = 448187817
| IUPAC_name = 
| image = Alsactide.png
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 34765-96-3
| ATC_prefix = V04
| ATC_suffix = CH04
| PubChem = 16129705
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07417
| ChemSpiderID = 17286506

<!--Chemical data-->
| C=99 | H=155 | N=29 | O=21 | S=1
| molecular_weight = 2119.54 g/mol
|  smiles = [H]/N=C(\N)/NCCC[C@@H](C(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCCCCN)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc5cnc[nH]5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc6ccc(cc6)O)NC(=O)CCN
|  StdInChI = 1S/C99H155N29O21S/c1-59(2)84(97(148)113-56-81(132)115-68(26-10-14-40-101)87(138)119-69(27-11-15-41-102)88(139)118-67(25-9-13-39-100)85(136)109-45-18-17-43-104)127-96(147)79-30-20-47-128(79)98(149)73(28-12-16-42-103)116-82(133)55-112-86(137)76(51-62-53-111-66-24-8-7-23-65(62)66)124-89(140)70(29-19-46-110-99(106)107)120-93(144)75(49-60-21-5-4-6-22-60)123-94(145)77(52-63-54-108-58-114-63)125-90(141)71(35-36-83(134)135)121-91(142)72(38-48-150-3)122-95(146)78(57-129)126-92(143)74(117-80(131)37-44-105)50-61-31-33-64(130)34-32-61/h4-8,21-24,31-34,53-54,58-59,67-79,84,111,129-130H,9-20,25-30,35-52,55-57,100-105H2,1-3H3,(H,108,114)(H,109,136)(H,112,137)(H,113,148)(H,115,132)(H,116,133)(H,117,131)(H,118,139)(H,119,138)(H,120,144)(H,121,142)(H,122,146)(H,123,145)(H,124,140)(H,125,141)(H,126,143)(H,127,147)(H,134,135)(H4,106,107,110)/t67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,84-/m0/s1
|  StdInChIKey = DIDCGVRALANKIU-OTEFFYEFSA-N
}}

'''Alsactide''' ([[International Nonproprietary Name|INN]]) (brand name '''Synchrodyn 1-17''' or simply '''Synchrodyn''', former development code name '''Hoechst 433'''), also known as '''alisactide''', is a [[Organic compound#Synthetic compounds|synthetic]] [[peptide]] and [[structural analog|analogue]] of [[adrenocorticotropic hormone]] (ACTH) which is used in [[Italy]] as a [[diagnostic]] [[pharmacological agent|agent]] in [[kidney]] function for [[adrenal insufficiency]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA34|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=34–}}</ref><ref>{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA33|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=33–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA12|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=12–}}</ref> Like ACTH, alsactide is thought to act as a non-selective [[agonist]] of the [[melanocortin receptor]]s, including the [[ACTH receptor]] (MC<sub>2</sub>R).[http://www.genome.jp/dbget-bin/www_bget?dr:D07417]{{Citation needed|date=May 2015}} However, it appears to show a different profile of [[receptor (biochemistry)|receptor]] [[binding selectivity|selectivity]] relative to ACTH, as it apparently demonstrated no evidence of inhibition of [[endogenous]] ACTH in [[Addison's disease]] patients.<ref name="Kontogeorgos2004">{{cite book|author=George Kontogeorgos|title=Molecular Pathology of the Pituitary|url=https://books.google.com/books?id=Atvixzf-d5wC&pg=PA66|date=1 January 2004|publisher=Karger Medical and Scientific Publishers|isbn=978-3-8055-7740-3|pages=66–}}</ref>

==See also==
* [[Tetracosactide]]

==References==
{{Reflist|2}}

{{Diagnostic agents}}
{{Melanocortin receptor modulators}}

[[Category:Hormonal agents]]
[[Category:Peptides]]
[[Category:Melanocortin receptor agonists]]